Meeting
2017 ASCO Annual Meeting
The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
Authors
Eric Xueyu Chen
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Eric Xueyu Chen , Derek J. Jonker , Hagen F. Kennecke , Sheryl L. Koski , Alice Chia-chi Wei , Nadine M Magoski , Dongsheng Tu , Christopher J. O'Callaghan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02870920
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3621)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3621
Abstract #
TPS3621
Poster Bd #
242b
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
First Author: Eric Xueyu Chen
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih
First Author: Eric Xueyu Chen
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande